Drugs / Atigotatug
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02949895 | Nov 2016 → Aug 2017 | small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02815592 | Nov 2016 → Dec 2019 | small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02247349 | Nov 2014 → Dec 2022 | small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06773910 | Mar 2025 → May 2032 expected | small cell lung carcinoma | SCRI Development Innovations, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04702880 | Mar 2021 → May 2025 | small cell lung carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06646276 | Feb 2025 → Apr 2028 expected | small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atigotatug | “Atigotatug is a first-in-class, fully human IgG1 antibody being developed for the treatment of SCLC.” NCT06773910 ↗ |
| Known as | BMS-986012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02247349 ↗ |
| Modality | Monoclonal antibody | “Atigotatug is a first-in-class, fully human IgG1 antibody being developed for the treatment of SCLC.” NCT06773910 ↗ |
| Route | Intravenous | “Intravenous solution” NCT02247349 ↗ |